AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

DSpace/Manakin Repository

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Citable link to this page

 

 
Title: AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Author: Batchelor, Tracy Todd; Sorensen, A; di Tomaso, Emmanuelle; Zhang, Wei-Ting; Duda, Dan Gabriel; Cohen, Kenneth S.; Kozak, Kevin R.; Cahill, Daniel P.; Chen, Poe-Jou; Zhu, Mingwang; Ancukiewicz, Marek; Mrugala, Maciej M.; Plotkin, Scott Randall; Drappatz, Jan; Louis, David N.; Ivy, Percy; Scadden, David Thomas; Benner, Thomas; Loeffler, Jay Steven; Wen, Patrick Yung Chih; Jain, Rakesh K.

Note: Order does not necessarily reflect citation order of authors.

Citation: Batchelor, Tracy T., A. Gregory Sorensen, Emmanuelle di Tomaso, Wei-Ting Zhang, Dan G. Duda, Kenneth S. Cohen, Kevin R. Kozak, et al. 2007. “AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients.” Cancer Cell 11 (1) (January): 83–95. doi:10.1016/j.ccr.2006.11.021.
Full Text & Related Files:
Abstract: Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of VEGF receptors—has rapid onset, is prolonged but reversible, and has the significant clinical benefit of alleviating edema. Reversal of normalization began by 28 days, though some features persisted for as long as four months. Basic FGF, SDF1α, and viable circulating endothelial cells (CECs) increased when tumors escaped treatment, and circulating progenitor cells (CPCs) increased when tumors progressed after drug interruption. Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor.
Published Version: 10.1016/j.ccr.2006.11.021
Other Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748664/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32631242
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters